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Abstract
The modulation of pentameric ligand-gated ion channels (pLGICs) by divalent cations is believed to play an important role
in their regulation in a physiological context. Ions such as calcium or zinc influence the activity of pLGIC neurotransmitter
receptors by binding to their extracellular domain and either potentiate or inhibit channel activation. Here we have
investigated by electrophysiology and X-ray crystallography the effect of divalent ions on ELIC, a close prokaryotic pLGIC
homologue of known structure. We found that divalent cations inhibit the activation of ELIC by the agonist cysteamine,
reducing both its potency and, at higher concentrations, its maximum response. Crystal structures of the channel in
complex with barium reveal the presence of several distinct binding sites. By mutagenesis we confirmed that the site
responsible for divalent inhibition is located at the outer rim of the extracellular domain, at the interface between adjacent
subunits but at some distance from the agonist binding region. Here, divalent cations interact with the protein via
carboxylate side-chains, and the site is similar in structure to calcium binding sites described in other proteins. There is
evidence that other pLGICs may be regulated by divalent ions binding to a similar region, even though the interacting
residues are not conserved within the family. Our study provides structural and functional insight into the allosteric
regulation of ELIC and is of potential relevance for the entire family.
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Introduction
The pentameric ligand-gated ion channels (pLGICs) are
ionotropic neurotransmitter receptors, which are activated by
the binding of ligands to specific sites of the protein. The family
includes both cation-selective channels, such as nicotinic Acetyl-
choline- (nAChRs) and Serotonin receptors (5HT3Rs), and anion-
selective channels, such as GABA- (GABARs) and Glycine
receptors (GlyRs) [1]. Despite these differences in ion selectivity,
the overall molecular architecture and the mechanism by which
ligands open the ion conduction path are conserved [2–8]. pLGIC
subunits form either homo- or hetero-pentamers that consist of at
least two functional units, an extracellular ligand-binding region
and a transmembrane pore [9,10]. Agonists open the channel by
binding to a conserved site in the extracellular domain, at the
interface between two subunits [11,12]. A homomeric receptor
contains five equivalent agonist binding sites, several of which
need to be occupied for maximum channel activation and this
makes the process highly cooperative [5,13–16]. Agonist binding is
accompanied by conformational rearrangements that are trans-
mitted over a distance of tens of angstroms from the extracellular
domain, via the domain interface to the pore [17]. These receptors
have thus become important model systems for the study of
allosteric mechanisms [18]. Many pLGICs are important drug
targets and all aspects of their function can be influenced by
pharmacological agents. These are a diverse set of molecules that
include agonists and competitive antagonists (which act on the
agonist binding site itself), pore blockers that inhibit ion
conduction, and allosteric modulators that interact with regions
distinct from the agonist-binding site. Modulators such as
benzodiazepines [19], general anesthetics [20], alcohol [21], and
the antiparasite ivermectin [22] can either enhance or inhibit
pLGIC activation. pLGIC function is affected also by divalent
cations (such as calcium and zinc) in two distinct ways. Cation-
selective pLGICs are somewhat permeable to divalents, but the
strong interaction between these ions and the pore decreases or
blocks conduction in a voltage-dependent manner [23,24]. In
addition to that, divalent cations can also modulate channel
gating. For instance, calcium potentiates the agonist responses of
nAChRs [25–27] and inhibits those of 5HT3Rs [28,29], and zinc
can either potentiate or inhibit channel activation, depending on
the type of pLGIC and the ion concentration [30–35].
Here we show that both the modulatory and the channel block
effects of divalent cations are present also in ELIC, a prokaryotic
pLGIC channel whose structure was determined in a noncon-
ducting conformation [36]. Agonists of ELIC include primary
amines such as cysteamine, propylamine, and the vertebrate
neurotransmitter GABA. In ELIC, these agonists occupy the
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canonical ligand-binding site of the family and open a cation-
selective pore with permeation properties similar to those of
eukaryotic channels [37]. Here we describe how divalent cations
permeate and block the ELIC pore, and how they also inhibit
ELIC gating, by binding in the extracellular domain, to a site
remote from the ligand-binding region.
Results
Modulation of ELIC Function by Divalent Ions
We have investigated the effects of divalent cations on ELIC by
electrophysiology and X-ray crystallography. Divalent cations can
influence ELIC function in several different ways depending on
concentration (Figure 1). The traces in Figure 1A show that low
mM concentrations of the alkaline earth metal ion Ca2+ decrease
the single channel conductance of ELIC when added to the
extracellular medium at negative holding potentials. ELIC single
channel currents are progressively reduced by increasing Ca2+
concentrations and decrease by approximately 25% of their
control amplitude at 5 mM Ca2+ (Figure 1C) and by a maximum
of about 50% at high Ca2+ concentration [37]. This effect is due to
tight interactions of divalent ions with the channel pore and has
been thoroughly characterized for different pLGIC family
members [23,24] including the homologous channel GLIC [38],
whose structure was determined by X-ray crystallography in a
conducting conformation [39,40].
Low extracellular calcium (greater than 100 mM) produces also
a voltage-independent decrease in agonist potency. This effect is
detectable at Ca2+ concentrations too low to decrease channel
conductance and is manifested as a parallel rightward shift in the
agonist dose–response curve (Figure 1D, Table S1). A similar effect
on agonist binding in the presence of calcium is observed in
isothermal titration calorimetry experiments (Figure 1E). Up to
1 mM calcium, the shift in the agonist dose–response curves is
truly parallel, as the maximum agonist current does not decrease
more than the single channel conductance does (Figure 1B and
1C). This pattern appears to reproduce the effects of competitive
antagonists, which bind to the ligand-binding site and reduce its
occupancy by the agonist in a surmountable way (e.g., their effect
can be overcome by increasing agonist concentration). This
resemblance is obvious if the effects of Ca2+ are compared with
those of the competitive antagonist acetylcholine, which is known
to bind to the agonist-binding site of ELIC (Figure 1F) [41]. The
Schild plot for acetylcholine [42,43] is linear with a slope of unity
and a binding affinity of 1.6 mM (Figure 1G, Table 1). The Schild
plot for Ca2+ is also linear, with a potency of 260 mM, but a
shallower slope of 0.8 (Figure 1G, Table 1).
The similarity between the effect of calcium and that of a
competitive antagonist disappears as Ca2+ concentrations are
increased above 1 mM. The current traces in Figure 1B show that
the reduction in agonist potency is now associated with a decrease
in the maximum agonist response. This decrease is too big to be
explained by the effect of Ca2+ on conductance: at 5 mM Ca2+ the
single channel conductance is reduced by 25% and the maximum
agonist response by 55% (Figure 1C). At progressively higher
concentrations of the divalent cation, the maximum current
response continues to decline and this decrease can be described
by a fit to a Langmuir equation with an IC50 of 6 mM (Figure 1H).
Despite the strong reduction in the maximum currents, the shift in
EC50 remains linear over a wide concentration range (Figure S1).
The pronounced drop in maximum current strongly suggests that
at higher concentrations calcium impairs the opening of the
channel and reduces agonist efficacy.
Next, we tried to establish whether calcium impairs the
maximum rate of ELIC gating (e.g., when the channel is fully
bound to the agonist) by measuring the on-relaxation of currents
elicited by rapid propylamine applications to outside-out patches
from HEK293 cells. Figure 1I shows that increasing Ca2+ from 50
to 200 mM does slow the onset of the current elicited by a
saturating agonist concentration (20 mM propylamine, red trace)
but that this effect is overcome by increasing agonist concentration
to 50 mM (green trace). Only minor changes in the time course of
deactivation were detected (Table 2). Thus the maximum rate with
which the agonist-bound channel opens is unchanged, which is
unexpected given the observed change in agonist efficacy. This
could be because we could test only low calcium (in high calcium
the concentrations of agonist required to saturate channel gating
are too high to be experimentally feasible). Alternatively, calcium
impairs gating by affecting a step in the channel activation that
controls the size of the maximum agonist response, but not the
speed of overall gating (see Discussion).
Finally, we found that divalent cations other than Ca2+ also
affect ELIC responses. In particular, other alkaline earth metal
ions, such as Mg2+, Sr2+, and Ba2+, are slightly weaker than Ca2+
in inhibiting ELIC (Figure 2A–C and E, Table 1, Table S1),
whereas the transition metal ion Zn2+ is considerably more potent
(i.e., Schild plot x-intercept 8 mM, Figure 2D and E, Table 1,
Table S1).
Structural Characterization of Divalent Ion Binding
In order to understand the structural basis of the effects of
divalent ions we aimed at identifying the region of interaction by
X-ray crystallography. Since the crystal form that was used for the
structure determination of ELIC contains high concentrations of
sulfate, which forms insoluble salts in the presence of most alkaline
earth metal ions, we had to identify novel crystallization conditions
compatible with divalent ions. In a broad screen we observed
crystals growing in Ba2+-acetate. Ba2+ can be readily located in the
electron density by its strong anomalous scattering properties, and
since it has comparable effects on channel function as Ca2+
(Figure 2A, Figure S2A), it is reasonable to assume that it will
Author Summary
Pentameric ligand-gated ion channels (pLGICs) are iono-
tropic neurotransmitter receptors that mediate electrical
signaling at chemical synapses. The pLGIC family includes
receptors for acetylcholine, serotonin, GABA and glycine,
which share a similar structural organization and activation
mechanism: the channels are closed in the absence of
ligands and open when neurotransmitters bind to a
conserved site in the extracellular domain. In many family
members, activation by the neurotransmitter can be
affected by modulators (including several drugs in
therapeutic use), which bind to different sites on the
channel. Channel function can be modulated also by
divalent cations, which either potentiate or inhibit pLGICs
at physiological concentrations. Here, we analyze this
mechanism in the pLGIC ELIC, a prokaryotic family
member of known structure. We show that divalent
cations such as calcium or zinc inhibit ELIC by occupying
an extracellular site remote from the ligand-binding region
thereby interfering with gating. Although the site of
interaction is not conserved between different family
members, we present evidence that regulation of other
pLGICs involves the same region. Our study has thus
provided insights into a regulatory process that appears to
be general for the pLGIC family in both eukaryotes and
prokaryotes.
Ca2+ Inhibition of ELIC
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occupy the same sites in the protein. Crystals of the ELIC/Ba2+
complex belong to two different, yet related crystal forms, one
similar to the original barium-free form of ELIC that was used for
structure determination (space group P21) and another growing in
a higher symmetry space group (P43) (Table 3). Datasets for both
crystal forms were collected to 3.8 A˚ (P21) and 3.3 A˚ (P43)
Figure 1. Inhibition of ELIC by calcium. (A) ELIC single channel currents in the presence of different extracellular concentrations of Ca2+ and all-
points amplitude histograms (recordings were from oocyte outside-out patches at 280 mV holding potential). (B) Maximum ELIC responses to
saturating concentrations of the agonist cysteamine in the absence and presence of Ca2+. Currents were measured from oocytes held at 240 mV
under two-electrode voltage clamp. Agonist application is indicated by a bar. Responses to cysteamine in the absence of extracellular Ca2+ are
followed by responses in the presence of Ca2+ (concentration in mM as shown) and by recovery application of cysteamine in the absence of Ca2+. (C)
Plot of maximum agonist responses and single channel currents at different Ca2+ concentrations. The currents are normalized to the control values (in
the absence of Ca2+). Maximum cysteamine currents (blue symbols) were measured with the two-electrode voltage clamp technique in oocytes as in
panel B. Single channel currents (green symbols) were measured in the outside-out configuration as in panel A. (D) Cysteamine dose–response
relationships for ELIC in the presence of different concentrations of Ca2+. (E) Equilibrium cysteamine binding isotherms determined by ITC for ELIC in
the absence (left) and presence of Ca2+. Solid curves represent fits to a single-site binding isotherm with Keff = 0.7 mM (no Ca2+) and 1.5 mM (0.6 mM
Ca2+), respectively. (F) Cysteamine dose–response relationships for ELIC in the presence of different concentrations of ACh. (G) Schild plot quantifying
the inhibition by Ca2+ and ACh. EC50 values were obtained from fits to data shown in panels (D) and (F). Potencies of the antagonists (pA values) were
obtained by linear regression, and the intersection with the x-axis is indicated (N). (H) Fraction of the maximum current response at different Ca2+
concentrations. The solid line shows a fit to a Langmuir equation with a Ki of 6 mM. The data presented in panels (C), (D), (F), and (H) are averages
from at least five oocytes; errors are SD. The solid lines in (D) and (F) show fits to a Hill equation. Currents were recorded at 240 mV. (I) Activation
kinetics of macroscopic currents of ELIC activated by propylamine in response to fast solution exchange at different Ca2+ concentrations. ELIC was
expressed in HEK 293 cells, and currents were recorded from excised patches in the outside-out configuration at 2100 mV.
doi:10.1371/journal.pbio.1001429.g001
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resolution and provide equivalent views of the channel and its
interaction with divalent cations.
The structures show a conformation of the channel that is
overall very similar to the structure of ELIC already described.
Strong peaks in the anomalous difference density allow us to detect
the presence of Ba2+ ions bound to three distinct sites of the
protein (Figure 3).
Firstly, a single Ba2+ ion per channel is located on the 5-fold axis
of symmetry at the extracellular end of the pore and is coordinated
by the side-chains of Asn251 (position 209 of the second
transmembrane domain in the numbering system developed for
the nAChR, Figure 3A–C). Throughout the article we will refer to
this site as Spore.
There are two additional sets of binding sites for Ba2+ in the
structure shown in Figure 3B. Both are found at the interface
between subunits in the extracellular domain in five symmetry-
related locations. One set of sites faces the channel vestibule and
will be referred to as Sin. The barium ion in Sin is coordinated by
Ser84 of the principal subunit and Asp86 of the complementary
subunit (Figure 3D). Barium ions are bound also to a set of five
equivalent sites on the outer rim of the extracellular domain
(Figure 3B and E). These sites, which we will call Sout, are about
15 A˚ below the ligand-binding pocket, towards the membrane
plane and are formed by the side-chains of acidic amino acids
contributed by both subunits. These residues include Asp113 at
the end of b6 on the principal side and Glu150 and Asp158 on the
loop connecting b8 and b9 on the complementary side (Figure 3A
and E). The refined 2Fo-Fc electron density map of this region
indicates a direct interaction of the respective carboxylate groups
with the bound ions resembling Ca2+-binding sites observed in
other proteins (Figure 3E, Figure S2B and C). Remarkably, in
none of the collected datasets did we find any evidence for Ba2+ in
the ligand-binding pocket itself.
Investigation of the Binding Sites of Divalent Ions by
Mutagenesis
The structure of ELIC in complex with Ba2+ has revealed the
location of three distinct sites for the interaction with divalent
cations. If binding to any of these sites is relevant for the inhibition
of the channel, we would expect that mutating the interacting
residues should affect the functional modulation by divalent ions.
Thus we mutated the residues that contact Ba2+ in the structure
and measured again the effects of Ca2+ by two-electrode voltage-
clamp electrophysiology (Figures 4 and 5, Table 1).
Given that the effects of low Ca2+ concentrations resemble those
of competitive antagonists, we tested also whether the agonist
binding site can play a role (even though we have no structural
evidence that divalents bind there). Our functional data show that
the agonist binding site is unlikely to be involved, because Ca2+
inhibition is not changed by a mutation here (R91A) that increases
agonist potency by 3–4-fold ([37], Figure 4A and F).
We then proceeded to investigate whether the inhibitory effects
of Ca2+ are produced via binding to the Spore site by truncating the
side-chain of the Asn residue in contact with the divalent ion. Our
X-ray crystallography data show that the structure of this N251A
mutant is on the whole similar to WT but lacks the anomalous
difference density in Spore. The structure of this mutant still shows
strong density of ions bound to Sout (and weaker density for Sin),
thus suggesting that effects of the mutation are local (Figure 4B).
Electrophysiological recording shows that agonists activate WT
and mutant N251A channels with similar potency and that the
inhibition by Ca2+ of these responses is only modestly decreased in
N251A (Figure 4C and Schild plots in 4F). This suggests that Spore
is not the major site responsible for the Ca2+ inhibition.
Figure 4F shows also that mutating the binding residues in
another set of divalent ion sites, Sin (which face the extracellular
vestibule), has little effect on Ca2+ inhibition. Mutation S84A (on
the principal side) changes neither the potency of the agonist nor
the inhibition by Ca2+ (Figure 4D). Similarly, in the mutant D86A
there is only a modest decrease in agonist potency, and the
inhibitory effect of Ca2+ is virtually unchanged (Figure 4E and F).
Thus we have shown that neither Spore nor Sin mediate the
functional effects of calcium on channel activation.
In contrast to that, we found that Ca2+ modulation is greatly
decreased when we change any of the residues that coordinate
divalent cations in Sout. This is seen both when the residues with
Table 1. Schild analysis of inhibition of ELIC.
ELIC Inhibitor pA Slope Ki
app [mM]
WT ACh 0.2160.06 1.060.1 1.6
WT Ca2+ 20.5760.03 0.860.05 0.26
WT/BAPTA Ca2+ 20.6960.11 1.060.3 0.20
WT Mg2+ 20.3660.02 0.960.01 0.43
WT Sr2+ 20.0760.02 0.960.02 0.85
WT Ba2+ 20.0760.01 1.160.03 0.85
WT Zn2+ 22.1660.13 1.260.01 0.007
R91A Ca2+ 20.6960.03 0.760.1 0.21
R91A ACh 20.7760.05 0.760.1 0.17
R91A TMA 0.7860.18 0.860.1 6.0
D86A Ca2+ 20.6060.11 0.860.1 0.25
S84A Ca2+ 20.8360.14 0.660.2 0.15
N251A Ca2+ 20.2760.19 0.960.2 0.53
D113A Ca2+ 0.6960.04 1.060.3 4.9
D113N Ca2+ 20.0260.08 1.060.01 0.95
D158A Ca2+ 0.7460.01 1.260.1 5.4
D158N Ca2+ 0.5060.17 0.560.2 3.2
E150A Ca2+ 0.2360.12 1.060.2 1.7
E150Q Ca2+ 0.0960.20 0.960.3 1.2
D113A/D158A Ca2+ N/D N/D N/D
D113A/D158A Ba2+ 0.8160.02 0.660.02 6.5
D113A/D158A Zn2+ N/D N/D N/D
D113A/D158A Ach 0.3260.06 0.860.1 2.1
WT/.25 mM Ca2+ Ach 0.0660.06 0.960.1 1.2
WT/.5 mM Ca2+ Ach 0.1160.09 0.960.01 1.3
WT/1 mM Ca2+ Ach 0.3560.01 1.160.01 2.2
WT/1 mM ACh Ca2+ 20.6560.01 0.960.02 0.22
doi:10.1371/journal.pbio.1001429.t001
Table 2. Activation and deactivation kinetics of ELIC.
Ca2+ (mM)
Propylamine
(mM) trise (ms) tdecay (ms) n
50 20 16.761.5 34.765.6 6
200 20 38.566.7 23.963.1 6
200 50 16.462.2 36.7612.7 6
50 20 19.663.1 33.566.9 6
doi:10.1371/journal.pbio.1001429.t002
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Figure 2. Inhibition of ELIC by different divalent cations. Dose–response relationships of ELIC activated by cysteamine at different
concentrations of Ba2+ (A), Sr2+ (B), and Mg2+ (C) and ELIC activated by propylamine at different concentrations of Zn2+ (D). (E) Schild plot quantifying
the inhibition by different divalent cations. EC50 values were obtained from fits to data shown in panels (A–D). Potencies of the Antagonists (pA
values) were obtained by linear regression, and the intersection with the x-axis is indicated. The data presented in panels (A–D) are averages from at
least 5 oocytes; errors are SD. The solid lines show fits to a Hill equation. Currents were recorded at 240 mV.
doi:10.1371/journal.pbio.1001429.g002
Table 3. Data collection and refinement statistics.
Crystallography WT Ba2+ WT Ba2+ N251A Ba2+ D113A/D158A Ba2+ WT TMAs
Data collection
Space group P43 P21 P21 P21 P21
Cell dimensions
a, b, c (A˚) 100.4, 100.4, 263.7 104.6, 267.5, 109.3 101.5, 268.5, 101.2 103.7, 266.7, 108.8 105.4, 266.8, 110.9
a, b, c (u) 90, 90, 90 90, 112.6, 90 90, 108.6, 90 90, 112.8, 90 90, 109.6, 90
Resolution (A˚) 40-3.3 40-3.8 40-3.7 40-4.4 40-4.0
Rmerge 12.5 (64.6) 11.9 (69.9) 11.8 (81.0) 12.6 (84.3) 11.0 (81.8)
I/sI 12.1 (2.7) 7.6 (2.1) 8.1 (2.1) 8.6 (2.5) 8.0 (1.5)
Completeness (%) 99.4 (96.6) 99.3 (99.0) 96.7 (96.2) 98.6 (97.7) 97.1 (85.6)
Redundancy 6.5 (6.1) 3.4 (3.5) 3.5 (3.6) 4.7 (4.7) 3.1 (3.0)
Refinement
Resolution (A˚) 20-3.3 30-3.8 30-3.7 30-4.4 30-4.0
Rwork/Rfree 22.7/25.8 25.5/27.2 24.5/27.4 21.6/23.9 25.6/27.0
Wilson B-factor 90 86 109 107 102
R.m.s. deviations
Bond lengths (A˚) 0.01 0.01 0.01 0.01 0.01
Bond angles (u) 1.2 1.2 1.0 1.3 1.2
Values in parentheses are for highest resolution shell. R.m.s., root mean square.
doi:10.1371/journal.pbio.1001429.t003
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acidic side chains (Asp 113, Glu150, and Asp158) are individually
replaced with their uncharged isosteric counterparts (Asn or Gln)
and when the acidic side-chains are truncated to Ala (Figure 5,
Figure S3). All of these mutations cause a variable but strong
decrease in the potency of Ca2+, which suggests that they weaken
the interaction with the ion and thus its inhibitory effects
(Figure 5E and F). The strongest effect among single mutants is
observed for residues Asp113 and Asp158 (Figure 5A, B, and E).
Combining these two mutations in the double mutant D113A/
D158A virtually abolishes the effects of both calcium and barium
on the agonist dose–response curves (Figure 5D, Figure S3E and
S3F). Remarkably, and in contrast to our observations in WT, in
this double mutant the decrease in Imax at high Ca
2+ concentration
appears entirely due to the reduction in single channel conduc-
tance (Figure 5G). The binding of Ca2+ to Sout is thus responsible
for both functional effects on the shift of the EC50 and the decrease
of Imax. Figure 5 also shows that mutations in Sout shift the EC50
towards higher agonist concentrations, an effect that is not
surprising given that this region is thought to be important in
transducing agonist binding into channel activation (Figure 5A–D,
Figure S3, Table S1).
The X-ray structure of the double mutant D113A/D158A in
complex with Ba2+ is on the whole unperturbed. The double
mutation has removed the density of ions bound to Sout, while
leaving the strong anomalous difference density in Spore un-
changed. This confirms that in this mutant divalents fail to
modulate channel activation because they cannot bind to the Sout
site (Figure 5H).
Given that the same mutations abolish also the modulation by
Zn2+ (Figure 5I), it is very likely that Zn2+ inhibits ELIC by
binding to the same site. This finding is somewhat unexpected as
Zn2+ usually interacts with histidine or cysteine residues. However,
since the ligand binding domain of ELIC does not contain any
cysteines and since mutations of the two histidines, which are both
located on b10, did not affect the inhibition by Zn2+ (Figure S4), it
is likely that the interaction of this transition metal ion with ELIC
occurs at this site and therefore deviates from common binding
modes.
Figure 3. Structure of ELIC in complex with divalent cations. (A) Sequence of ELIC with secondary structure elements indicated below.
Residues contributing to ion coordination in different sites are highlighted (Sin, yellow; Sout, red; Spore, cyan; Arg 91 in the ligand-binding pocket, Slig,
grey). (B) Anomalous difference electron density of ELIC in complex with Ba2+ superimposed on the structure of the ELIC pentamer (shown as ribbon
representation). Ion-binding sites are labeled. Close-up of Spore (C) and Sin (D). The protein is shown as Ca-trace with selected side-chains close to Ba
2+
(red sphere) shown as sticks. (E) Close-up of Sout. The protein is shown as Ca-trace with selected side-chains close to Ba
2+ (red sphere) shown as sticks.
The 2Fo-Fc electron density of a dataset from a crystal of space group P21 was calculated at 3.8 A˚ and contoured at 1 s (shown in cyan). The refined
model used to calculate phases did not contain Ba2+-ions. The anomalous difference electron densities shown in (B–E) (red mesh) were calculated
from the same dataset at 5 A˚ and contoured at 5 s. Crystals of space group P43 showed a qualitatively similar picture. Structures in Figures 3–7 were
prepared with DINO (www.dino3d.org).
doi:10.1371/journal.pbio.1001429.g003
Ca2+ Inhibition of ELIC
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Independence of Ca2+ and Acetylcholine Inhibition
The results of our mutational analysis strongly suggest that the
observed inhibition of ELIC by divalent cations is mediated by the
specific interaction with a site that is located at the outer rim of the
extracellular domain, at the interface between neighboring
subunits. Since this site is distant from the agonist-binding region,
we wanted to explore whether there is any direct competition
between the effect of divalent ions and that of competitive
antagonists binding to the ligand-binding site. Such competitive
antagonists include quaternary ammonium compounds such as
tetramethylammonium, a weak antagonist (Figure S5), or acetyl-
choline, which inhibits the channel with higher affinity. The X-ray
structure of ELIC in complex with the heavy atom analogue
tetramethylarsonium (Figure 6A) and the recently determined
structure of ELIC in complex with acetylcholine [41] show that
both antagonists bind to the ligand-binding pocket and prevent the
binding of the agonist to the same site. The overlap of agonist- and
antagonist-binding sites is also reflected in the 10-fold increase in
the Schild affinity of acetylcholine in the mutant R91A. This is
similar to the increase in agonist potency in the same mutant
(Figure 6B and D). In contrast to the mutation in the binding site,
the Sout double mutant D113A/D158A abolishes the modulatory
effect of Ca2+ but does not alter the affinity of acetylcholine (WT
1.6 mM, D113A/D158A 2.1 mM), confirming that calcium and
acetylcholine act via distinct sites (Figure 6C and F, Table 1).
Finally, in order to probe whether the presence of one
antagonist would alter the effect of the other, we have studied
the inhibition of ELIC by acetylcholine in the presence of different
concentrations of Ca2+ and vice versa. In no case did we find any
significant change in the potency of either antagonist, which
suggests that the inhibitory effects are additive and the two
compounds thus act independently (Figure 6E–H).
Discussion
In the present study we have investigated how divalent cations
modulate the function of ELIC, a bacterial member of the pLGIC
family. ELIC is inhibited by alkaline earth metal ions and by the
transition metal ion zinc. The modulation reported here resembles
similar effects observed in other family members, where divalent
cations act as either positive or negative modulators of gating. Ca2+
potentiates channel activity in a subset of nAChRs [26,27], whereas it
has an inhibitory effect on 5HT3Rs [29]. Like in ELIC, in 5HT3Rs
calcium shifts the EC50 of activation towards higher ligand
concentrations [29]. The action of Zn2+ appears to be more complex.
In some subtypes of GABARs, Zn2+ inhibits channel activity [31],
whereas in GlyRs, nAChRs, and 5HT3Rs, it acts as a potentiator at
low concentrations and as an inhibitor at higher concentrations
[30,32,33]. These opposing effects are believed to be mediated by the
successive occupation of binding sites of different affinity.
Divalent Ions Inhibit ELIC Gating by Binding to Sout
X-ray structures of ELIC crystals grown in the presence of
barium have allowed us to identify five structurally equivalent
Figure 4. Divalent ion inhibition in mutants of the nonregulatory sites Spore and Sin. Dose–response relationships of the ELIC point mutant
R91A (A) activated by cysteamine at different concentrations of Ca2+. (B) Anomalous difference electron density (calculated at 5 A˚ and contoured at 5
s) from data of the mutant N251A in complex with Ba2+ superimposed on a model of ELIC in ribbon representation. Ion-binding sites are indicated.
Dose–response relationships of the ELIC point mutants N251A (C), S84A (D), and D86A (E) activated by cysteamine at different concentrations of Ca2+.
The data presented in panels (A), (B), (D), and (E) are averages from at least 5 oocytes; errors are SD. The solid lines show fits to a Hill equation.
Currents were recorded at 240 mV. A dose–response curve of WT in the absence of Ca2+ (dashed line) is shown for comparison. (F) Schild plots
quantifying the inhibition of ELIC mutants by Ca2+. EC50 values were obtained from fits to data shown in panels (A), (B), (D), and (E). Potencies of the
antagonists (pA values) were obtained by linear regression; the intersection with the x-axis is indicated (N). WT is shown for comparison.
doi:10.1371/journal.pbio.1001429.g004
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binding sites (Sout) located at subunit interfaces on the extracellular
domain about 15 A˚ from the agonist-binding region. These are
likely to be responsible for the observed inhibition, as mutations at
this site have a strong effect on the potency of both Ca2+ and Zn2+.
The sites resemble regulatory calcium-binding pockets found in
other ion channel proteins, where the divalent ions interact with
the side chains of acidic residues that are often organized in
clusters on the protein sequence (Figure 7A) [44–46]. The
interaction found in ELIC is, however, not typical for zinc-
binding sites, as these usually contain either histidines or cysteines
for ion coordination [47–49], residues that are unlikely to play this
role in ELIC (Figure 7A, Figure S4).
While the residues that interact with divalent cations in ELIC
are not conserved across pLGICs, there is evidence that equivalent
modulatory effects in other pLGICs involve the same (Sout) region.
In the a7-nAChR, the residue Glu 172, which has been identified
as a key residue in the interaction with calcium [50–52], resides on
the same loop as Glu 150 and Asp 158 (loop 8) in ELIC. Similarly,
histidine and glutamate residues contributing to the interaction
with Zn2+ in GABAARs were mapped to the same location, at the
interface between two subunits [53], thus indicating that the Zn2+-
dependent inhibition of GABAARs may follow a similar mecha-
nism. Residues in the same loop of 5HT3Rs have also been
proposed to participate to calcium regulation of this receptor [54].
Figure 5. Divalent ion inhibition in mutants of the regulatory site Sout. Dose–response relationships of the ELIC mutants D113A (A) and
D158A (B), E150A (C), and the double mutant D113A/D158A (D) activated by cysteamine at different concentrations of Ca2+ are shown. (E) Schild plots
quantifying the inhibition of ELIC mutants by Ca2+. EC50 values were obtained from data shown in panels (A–D). Potencies of the antagonists (pA
values) were obtained by linear regression; the intersection with the x-axis is indicated (N). WT is shown for comparison. (F) Graphical depiction of
potencies for Ca2+ inhibition in different mutants. (G) Maximum current response of the double mutant D113A/D158A at different Ca2+
concentrations. The currents are normalized to the maximum response in the absence of Ca2+. Whole cell currents measured at 240 mV with the
two-electrode voltage clamp technique are shown in red (the averages of at least 5 oocytes are shown; errors are SD). Single channel currents from
the double mutant D113A/D158A were measured in the outside-out configuration and are shown in green. WT macroscopic and single channel
currents are shown as dashed lines for comparison. (H) Anomalous difference electron density (calculated at 5 A˚ and contoured at 5 s) from data of
the double mutant D113A/D158A in complex with Ba2+ is superimposed on a model of ELIC in ribbon representation. Ion-binding sites are indicated.
(I) Dose–response relationships of the double mutant D113A/D158A activated by propylamine at different concentrations of Zn2+. The data
presented in panels (A–D) and (I) are averages from at least 5 oocytes; errors are SD. The solid lines show fits to a Hill equation. Currents were
recorded at 240 mV. A dose–response curve of WT in the absence of Ca2+ (dashed line) is shown for comparison.
doi:10.1371/journal.pbio.1001429.g005
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Interestingly, a study on the 5HT3R has identified an aspartate
residue in the pore domain as an important determinant for
calcium-dependent inhibition. The equivalent Asn residue in
ELIC coordinates the barium ion in the site Spore [55]. We
investigated this site by mutagenesis but did not find any indication
for a similar role in the calcium regulation of ELIC. The
phenotypic difference may be due to a stronger interaction with a
divalent ion in the 5HT3R where the respective residue is an
aspartate and thus carries a negative charge (cf., an uncharged
asparagine in ELIC).
The Mechanism of Action of Divalent Ions
The effect of calcium and other divalent cations on gating of
ELIC results in a complex functional phenotype. At low
extracellular calcium concentrations, we see a reduction in agonist
potency that resembles competitive inhibition (with a linear Schild
plot with a slope near unity). Despite this resemblance, the agonist
binding site is not involved in this process and the presence of the
antagonist acetylcholine (which binds in the canonical agonist site)
has no effect on the action of calcium. Finally, higher calcium
concentrations reduce the maximum agonist response (to a greater
extent than can be accounted for by a conductance decrease). At
first sight, these effects appear to be too complex to be explained
by a single microscopic action of divalents (i.e., the binding of Ca2+
to the site Sout). However, they can all be accounted for, if calcium
impairs a single step of ELIC activation, for example channel
opening, provided gating is efficient in wild-type ELIC (i.e., the
agonist efficacy E is high to start with, Figure 7B). This is a
plausible hypothesis, given the high open probability of the single
channel activity in Figure 1A.
In first approximation, the relation between maximum open
probability Pmax and efficacy E is:
Figure 6. Inhibition by ACh. (A) Anomalous difference electron density (calculated at 5 A˚ and contoured at 6 s) from data of WT in complex with
TMAs is superimposed on a model of ELIC in ribbon representation. The ligand-binding site is indicated. Dose–response relationships upon activation
with cysteamine of the ELIC mutants R91A (B) and the double mutant D113A/D158A (C) at different concentrations of ACh. (F) Schild plots
quantifying the inhibition of ELIC mutants by ACh. EC50 values were obtained from data shown in panels (B–C). Dose–response relationships upon
activation with cysteamine of WT in the presence of either 0.25 (E), 0.5 (F), or 1 mM Ca2+ (G). (H) Schild plots quantifying the inhibition of ELIC
mutants by ACh in the presence of Ca2+. EC50 values were obtained from data shown in panels (E–G). Potencies of the antagonists (pA values) were
obtained by linear regression; the intersection with the x-axis is indicated (N). The data presented in panels (B–C) and (E–G) are averages from at least
5 oocytes; errors are SD. The solid lines show fits to a Hill equation. Currents were recorded at 240 mV. A dose–response curve of WT in the absence
of ACh and Ca2+ (dashed line) is shown for comparison.
doi:10.1371/journal.pbio.1001429.g006
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Pmax~
E
Ez1
,
and our observations of an ELIC Pmax greater than 95% are
compatible with values of E that are greater than 20 (as reported
for other pLGIC such as nicotinic and glycine receptors). If the
value of E is high to start with, the reduction in efficacy produced
by divalents must be substantial before a decrease in maximum
response becomes apparent. That is why it is seen only at high
calcium concentrations. More modest decreases in efficacy, at low
calcium concentrations, will cause only a decrease in agonist
Figure 7. Potential mechanisms. (A) Interactions in the regulatory divalent ion-binding site of ELIC (left) in comparison with a regulatory Ca2+
binding site of the BK-channel (middle) and the Zn2+-transporter YiiP (right). (B) Schematic model of a potential mechanism for the inhibitory effect of
divalent ions. The two rows show simplified schemes for channel activation in control conditions (top) and in the presence of divalent ions. From left
to right, the schemes show that binding of agonist molecules (red ovals) to the extracellular domain (with microscopic affinity Kd) is followed by
conformational changes (yellow background) that result in channel opening. Channel gating (described by the efficacy equilibrium constant E) is
impaired when the channel is bound to divalent ions (yellow circles, ECa
2+). The decrease in agonist efficacy is likely to be due to a change in the rate
of opening, as shown by the size of the arrows in the last step of the reaction. (C) Schematic mechanism of how binding sites located on similar
places of an oligomeric channel could alternately stabilize the closed or open conformation of the channel.
doi:10.1371/journal.pbio.1001429.g007
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potency. This is because agonist EC50 is directly affected by the
value of E. In the simplest del Castillo-Katz model, EC50 is given
by:
EC50~
Kd
Ez1
,
where Kd is the microscopic dissociation constant of the agonist
(Figure 7B) [56].
It can also be shown (Text S1) that the effects of calcium and
those of a competitive antagonist are expected to be independent,
if we model equilibrium channel activation with a simple scheme,
where calcium binding impairs gating (by affecting E) and the
antagonist binds to the resting form of the channel. This model not
only predicts Schild-like behavior for the effect of calcium but
suggests also that the Schild intercept is a reasonable estimate for
the microscopic affinity of divalents (Text S1).
These conclusions are unchanged if we model channel
activation by a more detailed and realistic activation scheme,
incorporating an intermediate state between agonist binding and
channel opening. The existence of one or more gating interme-
diate states for channels in the nicotinic superfamily is supported
by several lines of evidence. For instance, Q analysis in muscle
nicotinic AChRs [57] indicates that blocks of residues move
asynchronously in the gating conformational change. In addition
to that, mechanisms with reaction intermediates (referred to as flip,
primed, or catch-and-hold [13,58–61]) are needed to explain
several aspects of the function of the GlyR and the muscle
nicotinic AChR, such as agonist efficacy (Figure 7B). In our
experiments, the presence of an additional intermediate step that
limits the maximum rate of current onset in agonist-bound ELIC
channels is required to explain the results of our agonist
concentration jumps. This is because we observed that low
calcium increased the agonist concentration needed to achieve the
maximum rate of current onset, but did not change the limiting
rate of channel gating. If activation went through a single
conformational step as the channel gates (as in a simple del
Castillo-Katz mechanism), this single step would control both the
rate of current onset for the agonist-bound channel and the
maximum response, and any changes in this would be experi-
mentally detectable (see Text S1).
Conclusions
In our study we have shown how the binding of calcium to a
single site remote from the ligand binding pocket modulates the
activation of the pLGIC ELIC. Given that divalent ions impair
ELIC gating, they are expected to bind more tightly to the resting
state of the channel and stabilize it. The location of the divalent
binding site at the interface between adjacent subunits is an
intriguing mechanism to stabilize distinct states in an allosteric
protein, given that these regions are involved in conformational
changes (Figure 7C). Thus, occupancy by divalent ions of sites at a
similar location in the different pLGICs will result in potentiation
or inhibition, depending on whether the equilibrium is shifted
towards conducting or nonconducting conformations. Allosteric
modulation is important for the pharmacology of pLGICs, as
many of pLGIC drugs in therapeutic use act by this mechanism,
although by binding to sites distinct from those of divalent ions.
Modulation by divalent ions of pLGICs occurs at concentra-
tions that are physiologically relevant in vertebrates and may
regulate the activity of channels in their natural environment
[31,62]. It is not known whether such regulation is important for
ELIC activity in its natural host Erwinia chrysanthemi, but it is
remarkable that the observed mechanism has been conserved
during evolution.
Materials and Methods
Protein Expression and Purification
ELIC WT and point mutants were expressed and purified as
described [36,37]. E. coli BL21DE3 containing a vector encoding
for a fusion protein consisting of the pelB signal sequence, a His10
tag, maltose binding protein, a HRV 3C protease site, and ELIC
were grown in M9 minimal medium at 37uC to an OD of 1.0 and
subsequently cooled to 20uC. Expression was induced by addition
of 0.3 mM IPTG and carried out overnight. All the following steps
were performed at 4uC. The protein was extracted from isolated
membranes in a buffer containing 1% n-Undecyl-b-D-Maltoside
(UDM, Anatrace, Inc.) and purified by Ni-NTA chromatography
(Qiagen). The purified MBP-ELIC-fusion protein was digested
with HRV 3C protease to cleave the His10-MBP protein. His10-
MBP and 3C protease were subsequently removed from solution
by binding to Ni-NTA resin. ELIC was concentrated and
subjected to gel-filtration on a Superdex 200 column (GE
Healthcare). The protein peak corresponding to the ELIC
pentamer was pooled and concentrated to 10 mg/ml and used
for crystallization.
Crystallization and Structure Determination
The purified protein was crystallized in sitting drops at 4uC.
Protein containing additional 0.5 mg/ml E. coli polar lipids (Avanti
Polar Lipids, Inc.) was mixed in a 1:1 ratio with reservoir solution
(50 mM ADA pH 6.5, 50 mM BaAc2, and 10% (w/v) PEG4000).
The crystals were cryoprotected by transfer into solutions
containing 30% ethyleneglycol. All datasets were collected on
frozen crystals on the X06SA beamline at the Swiss Light Source
(SLS) of the Paul Scherrer Institut (PSI) on a PILATUS detector
(Dectris). The data were indexed, integrated, and scaled with XDS
[63] and further processed with CCP4 programs [64]. The
structure of WT and mutants in space groups P43 and P21 were
determined by molecular replacement in PHASER [65] using the
ELIC pentamer (2VLO) as a search model. G164, which was not
included in the original model (2VLO), was introduced according
to the structure of the ELIC acetylcholine complex (3RQW). The
absence of this amino acid had only a local effect and did not
influence the location of neighboring residues. The model was
rebuilt in Coot [66] and refined maintaining strong NCS
constraints in PHENIX [67]. R and Rfree were monitored
throughout. Rfree was calculated by selecting 5% of the reflection
data in thin slices that were selected for the initial dataset of ELIC
and that were omitted in refinement.
Isothermal Titration Calorimetry
Binding of the agonist propylamine to ELIC in the presence and
absence of calcium was measured by isothermal titration
calorimetry (ITC) with a MicroCal ITC200 system (GE
Healthcare). The syringe was loaded with agonist solution
containing 30–37 mM propylamine dissolved in measurement
buffer (containing 25 mM Tris-HCl pH8.5, 150 mM NaCl, and in
certain experiments 0.6 mM CaCl2). The sample cell was loaded
with 300 ml of purified ELIC in measurement buffer containing
0.9 mM UDM at a concentration between 80 and 110 mM.
Agonist was applied by sequential injections of 2 ml aliquots
followed by a 180 s equilibration period after each injection. The
data were recorded at 4uC and analyzed by a fit to a single-site
binding isotherm.
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Two-Electrode Voltage Clamp Recording
Constructs containing the gene of either the WT or mutant
channels preceded by the signal sequence of the chicken a7nAchR
were cloned into the pTLN vector for expression in X. laevis
oocytes [68]. After linearization of the plasmid DNA by MluI,
capped complementary RNA was transcribed with the mMessage
mMachine kit (Ambion) and purified with the RNeasy kit
(Qiagen). For expression, 1–50 ng of RNA was injected into
defolliculated oocytes. Two-electrode voltage clamp measurements
were performed 1 d after injection at 20uC (OC-725B, Warner
Instrument Corp.). Currents were recorded in bath solutions
containing 10 mM HEPES (pH 7), 130 mM NaCl, and the
indicated concentrations of cysteamine and divalent cations. In
case of solutions containing Zn2+, cysteamine was replaced by
propylamine. The membrane potential in all dose–response
measurements was set to 240 mV. As ELIC is permeable to
divalent cations, we tested if endogenous calcium-activated
chloride channels affected our measurements. To chelate intra-
cellular calcium ions, the oocytes were incubated for 15 to 30 min
in bath solutions lacking divalent ions but containing 10 mM
BAPTA-AM. Dose–response curves in the presence of calcium
obtained from BAPTA-AM-treated oocytes did not differ from the
measurements of the untreated oocytes even at elevated Ca2+
concentration (Figure S6). The lack of a significant effect is likely
due to the strong outward-rectification of calcium-activated
chloride channels, which do not pass significant currents at
negative voltages.
Patch Clamp Recording in X. oocytes
X. laevis oocytes were transferred to a hyperosmotic solution to
manually remove the vitelline layer. Membrane patches were
recorded in the excised outside-out configuration 3–5 d after
injection of mRNA with an Axopatch 200B amplifier (Axon
Instruments) at 20uC. Data were sampled at 100 ms, filtered with
1,000 Hz, and analyzed using Clampfit (Axon Instruments, Inc.).
Bath solutions contained 10 mM HEPES (pH 7.0), 150 mM
NaCl, and indicated concentrations of ligands and divalent
cations. Electrodes had a resistance of 3–5 MV. Pipette solutions
contained 150 mM NaCl, 10 mM EGTA, 5 mM MgCl2, and
10 mM HEPES at pH 7.0. Bath electrodes were placed in 1 M
KCl solution connected to the bath solution by Agar bridges. The
agonists were applied to the patch using a stepper motor (SF77B
Perfusion fast step, Warner).
Patch Clamp Recording in HEK 293 Cells
Human embryonic kidney 293 cells (American Type Culture
Collection-CRL-1573;LGC Promochem) were maintained at
37uC in a 95% air/5% CO2 incubator in DMEM supplemented
with 0.11 g/l sodium pyruvate, 10% (v/v) heat-inactivated fetal
bovine serum, 100 U/ml penicillin G, 100 mg/ml streptomycin
sulfate, and 2 mM L-glutamine (Invitrogen). Cells (passaged every
2 d, up to 30 times) were plated and transfected by calcium
phosphate-DNA coprecipitation [69], with a total amount of DNA
of 3 mg/dish (82% ELIC and 18% eGFP DNA, both subcloned in
pcDNA3).
Cells were bathed in an extracellular solution containing (mM):
150 KCl, 0.05 or 0.2 CaCl2, and 10 HEPES, pH adjusted to 7.4
with KOH (osmolarity 310 mOsm). Patch pipettes were pulled
from thick-walled borosilicate glass (GC150F; Harvard Apparatus)
and fire polished to a resistance of 8–12 MV. Intracellular solution
contained (mM): 150 KCl, 0.5 CaCl2, 5 EGTA, and 10 HEPES,
pH adjusted to 7.4 with KOH. Agonist-evoked currents were
recorded at 20uC with an Axopatch 200B amplifier (Molecular
Devices) from outside-out patches held at 2100 mV. Patches were
stepped to this holding voltage 0.2 s before the agonist was applied
and otherwise held at 240 mV. No correction for junction
potential was applied (calculated value 0.2 mV). Currents were
filtered at 5 kHz, digitized at 50 kHz with Digidata 1322A, and
saved directly on computer with Clampex software (all MDS
Analytical Technologies).
All concentration jumps were performed using a piezo stepper
(Burleigh instruments) with an application tool made from theta
tube glass (Hilgenberg; final tip diameter, 150 mm). Voltage
commands for the piezo stepper were 200 ms square pulses
conditioned by low-pass eight-pole Bessel filtering (23 dB
frequency 5 kHz) to smooth oscillations. Actual exchange time
was estimated by recording the open-tip response to the
application of diluted extracellular solution (70% water) after
rupture of the patch. Only patches in which the 20%–80%
exchange time was faster than 250 ms were included in the
analysis.
Agonist solutions were freshly prepared every day from 1 M
stock solutions. Propylamine was applied at a concentration
known to elicit maximum response (20 mM and 50 mM, for 50
and 200 mM Ca2+, respectively). Traces shown are averages of 5 or
10 individual agonist currents, separated by at least 10 s.
Responses were averaged, and the time course of activation and
deactivation (between 95% and 5% of the peak current level) was
fitted with one exponential component (program Clampfit 9.0).
Accession Code
The coordinates of the P43 crystal form of ELIC in complex
with Ba2+ have been deposited with the Protein Data Bank under
code 2yn6.
Supporting Information
Figure S1 Dose–response relationships at high Ca2+ concentra-
tions. Cysteamine dose–response relationships of ELIC in the
presence of different concentrations of Ca2+. Currents were
recorded at 240 mV. The data are averages from at least 5
oocytes; errors are SD. The solid lines show fits to a Hill equation.
(B) Schild plot quantifying the inhibition by Ca2+. EC50 values
were obtained from fits to data shown in panel (A). Potencies of the
antagonists (pA values) were obtained by linear regression; the
intersection with the x-axis is indicated (N).
(JPG)
Figure S2 Barium binding. (A) Plot of maximum agonist
responses and single channel currents at different Ba2+ concen-
trations. The currents are normalized to the control values (in the
absence of Ba2+). Maximum cysteamine currents (blue symbols)
were measured with the two-electrode voltage clamp technique.
Single channel currents (green symbols) were measured from
excised patches in the outside-out configuration. (B, C) Structure
of the divalent cation binding site Sout. Stereo representations of
the binding region in two different crystal forms. The protein is
shown as Ca-trace with selected side-chains close to Ba2+ (red
sphere) shown as sticks. 2Fo-Fc electron densities are shown as
cyan mesh. The refined models used to calculate phases did not
contain Ba2+-ions. (B) Space group P43. The 2Fo-Fc electron
density was calculated at 3.3 A˚ and contoured at 1 s. The
anomalous difference electron density (calculated at 5 A˚ and
contoured at 5 s) was obtained from the same dataset. (C) Space
group P21. The 2Fo-Fc electron density was calculated at 3.8 A˚
and contoured at 1 s. The anomalous difference electron density
(calculated at 5 A˚ and contoured at 5 s) was obtained from the
same dataset.
(JPG)
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Figure S3 Divalent ion inhibition in mutants of the regulatory
site Sout. Dose–response relationships of the ELIC mutants D113N
(A), D158N (B), and E150Q (C) activated by cysteamine at
different concentrations of Ca2+ are shown. (D) Schild plots
quantifying the inhibition of ELIC mutants by Ca2+. (E) Dose–
response relationships of the ELIC double mutant D113A/D158A
activated by cysteamine at different concentrations of Ba2+ are
shown. (F) Schild plot quantifying the inhibition of the ELIC
double mutant D113A/D158A by Ba2+. EC50 values were
obtained from data shown in panels (A–C) and (E). Potencies of
the antagonists (pA values) in (D) and (F) were obtained by linear
regression; the intersection with the x-axis is indicated (N). WT is
shown for comparison. The data presented in panels (A–C) and (E)
are averages from at least 5 oocytes; errors are SD. The solid lines
show fits to a Hill equation. Currents were recorded at 240 mV.
A dose–response curve of WT in the absence of Ca2+ (dashed line)
is shown for comparison.
(JPG)
Figure S4 Divalent ion inhibition in mutants of histidine
residues in the extracellular domain. Dose–response relationships
of the ELIC mutants H168A (A) and H176A (B) activated by
cysteamine at different concentrations of Ca2+ are shown. (C)
Schild plots quantifying the inhibition of ELIC mutants by Ca2+.
EC50 values were obtained from data shown in panels (A–B).
Potencies of the antagonists (pA values) were obtained by linear
regression; the intersection with the x-axis is indicated (N). WT is
shown for comparison. The data presented in panels (A–B) are
averages from at least 5 oocytes; errors are SD. The solid lines
show fits to a Hill equation. Currents were recorded at 240 mV.
A dose–response curve of WT in the absence of Ca2+ (dashed line)
is shown for comparison.
(JPG)
Figure S5 Inhibition by tetramethylammonium (TMA). Dose–
response relationships of WT (A) and the mutant R91A (B)
activated by cysteamine at different concentrations of TMA are
shown. A dose–response curve of WT in the absence of TMA
(dashed line) is shown for comparison. (C) Schild plots quantifying
the inhibition by TMA. EC50 values were obtained from data
shown in panels (A–B). Potencies of the antagonists (pA values)
were obtained by linear regression; the intersection with the x-axis
is indicated (N). WT is shown for comparison. The data presented
in panels (A–B) are averages from at least 5 oocytes; errors are SD.
The solid lines show fits to a Hill equation. Currents were recorded
at 240 mV.
(JPG)
Figure S6 Ca2+ inhibition measured from BAPTA-AM-treated
oocytes. Dose–response relationships of WT activated by cyste-
amine at different concentrations of Ca2+ are shown. To chelate
intracellular Ca2+, oocytes were incubated in solutions lacking
divalent ions but containing 10 mM Bapta-AM. (C) Schild plots
comparing the inhibition of ELIC in BAPTA-treated oocytes by
Ca2+. EC50 values were obtained from data shown in panel (A).
Potencies of the antagonists (pA values) were obtained by linear
regression; the intersection with the x-axis is indicated (N). WT from
oocytes treated by standard procedures is shown for comparison.
The data presented in panel (A) are averages from at least 5
oocytes; errors are SD. The solid lines show fits to a Hill equation.
Currents were recorded at 240 mV.
(JPG)
Table S1 Dose–response relationships of agonists in the
presence of different modulators.
(DOC)
Text S1 Supplementary discussion.
(DOCX)
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